Spotlight on Pediatrics

Credits: 1.00 CME
Issues and Updates in Hereditary Angioedema
Marc Riedl, MD, MS
University of California, San Diego School of Medicine

Issues and Updates in Hereditary Angioedema

Start

Jointly Provided By

University of California, San Diego School of Medicine and RMEI Medical Education, LLC.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 27, 2017
Expires: December 27, 2018
1.0 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of allergy/immunology physicians, allergy/immunology NPs and PAs, dermatology physicians, dermatology NPs and PAs.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH)
  2. Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use

Activity Description

This interactive multi-challenge activity addresses issues and updates in HAE. Based on the proceedings from a live continuing medical education series, it contains slides, expert audio, and commentary on some of the most current and important topics in HAE. Patient case challenges allow you to test your knowledge and skill in diagnosing and treating this important disease. Commentary from faculty experts will increase your understanding of the newest developments in HAE.

Statement of Educational Need

The treatment of hereditary angioedema (HAE) is rapidly evolving. After many years of limited treatment options, several effective medications for HAE have been introduced into clinical practice over the past 8 years. Now, a second wave of novel therapies are poised to reach the clinic. While the impact of these treatments is not yet known, it is likely the HAE treatment paradigm will shift yet again given the broadening therapeutic options available to physicians and patients.

Faculty

Marc A. Riedl, MD, MS
Professor of Medicine 
Clinical Director, US HAEA Angioedema Center 
Division of Rheumatology, Allergy and Immunology 
University of California, San Diego 
San Diego, CA


Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director 
Medical Research of Arizona 
Allergy, Asthma & Immunology Associates, Ltd. 
Scottsdale, AZ


Daniel F. Soteres, MD, MPH
Physician Partner
Asthma & Allergy Associates and Research Center
Colorado Springs, CO


Disclosure of Conflicts of Interest

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Marc A. Riedl, MD, MS, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Ionis, Pharming, Shire (Research); Adverum, Alnylam, BioCryst, CSL Behring, KalVista, Pharming, Shire (Consulting Fees)
  • Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, Dyax, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Dyax, Pharming, Shire (Research); CSL Behring, Pharming, Shire (Advisory Board); CSL Behring (Consulting Fees)
  • Daniel F. Soteres, MD, MPH, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); CSL Behring, Shire (Research); CSL Behring, Shire (Advisory Board); CSL Behring, Pharming, Shire (Consulting Fees)

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, San Diego School of Medicine and RMEI Medical Education, LLC. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of California, San Diego School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural Competency
This activity is in compliance with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum in the subjects of cultural and linguistic competencies. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables healthcare professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and Linguistic Competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UC San Diego CME website at http://cme.ucsd.edu.

How to Receive Credit

The estimated time to complete this activity is 1 hour. To obtain credit, participants should view the presentation, answer the multiple-choice post-test questions, and complete the evaluation form online to receive a certificate.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

The activity is supported in part by educational grants from CSL Behring, Pharming Healthcare, Inc., and Shire.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Pediatrics Presentations

1.00 CME
University of California, San Diego School of Medicine
Issues and Updates in Hereditary Angioedema

Issues and Updates in Hereditary Angioedema

Start

Jointly Provided By

University of California, San Diego School of Medicine and RMEI Medical Education, LLC.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: December 27, 2017
Expires: December 27, 2018
1.0 hour to complete

Media

Internet

Target Audience

This activity has been designed to meet the educational needs of allergy/immunology physicians, allergy/immunology NPs and PAs, dermatology physicians, dermatology NPs and PAs.

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Recognize the possibility of hereditary angioedema (HAE) in patients who present with angioedema and integrate a diagnostic workup for angioedema that includes analysis for the various types of HAE (Type I, Type II, and normal C1-INH)
  2. Incorporate current, novel, and emerging treatments for HAE based on an understanding of their efficacy, safety, and guidance for use

Activity Description

This interactive multi-challenge activity addresses issues and updates in HAE. Based on the proceedings from a live continuing medical education series, it contains slides, expert audio, and commentary on some of the most current and important topics in HAE. Patient case challenges allow you to test your knowledge and skill in diagnosing and treating this important disease. Commentary from faculty experts will increase your understanding of the newest developments in HAE.

Statement of Educational Need

The treatment of hereditary angioedema (HAE) is rapidly evolving. After many years of limited treatment options, several effective medications for HAE have been introduced into clinical practice over the past 8 years. Now, a second wave of novel therapies are poised to reach the clinic. While the impact of these treatments is not yet known, it is likely the HAE treatment paradigm will shift yet again given the broadening therapeutic options available to physicians and patients.

Faculty

Marc A. Riedl, MD, MS
Professor of Medicine 
Clinical Director, US HAEA Angioedema Center 
Division of Rheumatology, Allergy and Immunology 
University of California, San Diego 
San Diego, CA


Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director 
Medical Research of Arizona 
Allergy, Asthma & Immunology Associates, Ltd. 
Scottsdale, AZ


Daniel F. Soteres, MD, MPH
Physician Partner
Asthma & Allergy Associates and Research Center
Colorado Springs, CO


Disclosure of Conflicts of Interest

It is the policy of the University of California, San Diego School of Medicine to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms: 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Marc A. Riedl, MD, MS, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Ionis, Pharming, Shire (Research); Adverum, Alnylam, BioCryst, CSL Behring, KalVista, Pharming, Shire (Consulting Fees)
  • Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, Dyax, Pharming, Shire (Speakers Bureau); BioCryst, CSL Behring, Dyax, Pharming, Shire (Research); CSL Behring, Pharming, Shire (Advisory Board); CSL Behring (Consulting Fees)
  • Daniel F. Soteres, MD, MPH, has affiliations with CSL Behring, Pharming, Shire (Speakers Bureau); CSL Behring, Shire (Research); CSL Behring, Shire (Advisory Board); CSL Behring, Pharming, Shire (Consulting Fees)

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose.

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, San Diego.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, San Diego School of Medicine and RMEI Medical Education, LLC. The University of California, San Diego School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of California, San Diego School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cultural Competency
This activity is in compliance with California Assembly Bill 1195 which requires CME courses with patient care components to include curriculum in the subjects of cultural and linguistic competencies. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables healthcare professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and Linguistic Competency was incorporated into the planning of this activity. Additional resources on cultural and linguistic competency and information about AB1195 can be found on the UC San Diego CME website at http://cme.ucsd.edu.

How to Receive Credit

The estimated time to complete this activity is 1 hour. To obtain credit, participants should view the presentation, answer the multiple-choice post-test questions, and complete the evaluation form online to receive a certificate.

Physicians/DOs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

The activity is supported in part by educational grants from CSL Behring, Pharming Healthcare, Inc., and Shire.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.